( September 12, 2025, 8:30 AM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court requested a response from Novartis Pharmaceuticals Corp. to generic drugmakers’ petition for a writ of certiorari in response to the petitioners’ argument that the Federal Circuit U.S. Court of Appeals wrongly considered after-arising technology in a dispute over the patent for heart medication Entresto....